Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 210 of 318 results for breast cancer

  1. Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.

    combination with a taxane for the first-line treatment of metastatic breast cancer Number TA214 Date issued February 2011 Other

    Research recommendation
    Published
    9 June 2015

  2. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013

  4. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Withdrawn guidance

  5. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA1129)

    Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    12 February 2026
    View recommendations

    Sections for TA1129

  6. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development Reference number: GID-TA11022 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

    Awaiting development Reference number: GID-TA11971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

    Awaiting development Reference number: GID-TA11987 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Caris Molecular Intelligence for guiding cancer treatment (MIB120)

    NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .

    Medtech innovation briefing
    Published
    20 September 2017

  10. What is the role of arm and shoulder specific exercises compared with and/or used as an adjunct to established lymphoedema treatments (such as compression garments and complex decongestive therapy)?

    Source guidance details Comes from guidance Advanced breast cancer: diagnosis and treatment Number CG81 Date issued

    Research recommendation
    Published
    6 July 2015

  11. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)

    Evidence-based recommendations on talazoparib (Talzenna) with enzalutamide (Xtandi) for untreated hormone-relapsed metastatic prostate cancer.

    Technology appraisal guidance
    Published
    11 February 2026
    View recommendations

    Sections for TA1130

  12. Cough (acute): antimicrobial prescribing (NG120)

    This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    7 February 2019
    View recommendations

    Sections for NG120

  13. Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

    Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.

    Technology appraisal guidance
    Last updated
    8 February 2021
    View recommendations

    Sections for TA185

  14. Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]

    Awaiting development Reference number: GID-TA11862 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]

    Discontinued Reference number: GID-TA10327

    Technology appraisal guidance
    Discontinued